Norrie disease is a rare, X-linked genetic syndrome characterized by combined congenital blindness and progressive hearing impairment. Norrie disease is caused by alterations in the NDP gene encoding the growth factor norrin that plays a key role in vascular development and stabilization of the eye, inner ear and brain. We identified a family with 3 affected deafblind males and a single female carrier presenting with a serous retinal detachment but normal hearing. Genetic analysis revealed a novel c.277T>C missense mutation causing the substitution of a hydrophobic cysteine to a hydrophilic arginine [p.(Cys93Arg)] within the highly conserved cysteine knot domain of the norrin protein. These results should expand the scope for amniocentesis and genetic testing for Norrie disease which is gaining in importance due to novel postnatal therapeutic concepts to alleviate the devastating retinal symptoms of Norrie disease.

Keywords:
Norrie disease, Syndromic deafness, Hereditary hearing loss, Deafblindness
1.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
2.
Allen RC, Russell SR, Streb LM, Alsheikheh A, Stone EM: Phenotypic heterogeneity associated with a novel mutation (Gly112Glu) in the Norrie disease protein. Eye (Lond) 2006;20:234-241.
3.
Arnold K, Bordoli L, Kopp J, Schwede T: The Swiss-model workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006;22:195-201.
4.
Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N: Consurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res 2010;38:W529-W533.
5.
Berger W, Meindl A, van de Pol TJ, Cremers FP, Ropers HH, Doerner C, Monaco A, Bergen AA, Lebo R, Warburg M, et al: Isolation of a candidate gene for Norrie disease by positional cloning. Nat Genet 1992a;1:199-203.
6.
Berger W, van de Pol D, Bachner D, Oerlemans F, Winkens H, Hameister H, Wieringa B, Hendriks W, Ropers HH: An animal model for Norrie disease (ND): gene targeting of the mouse ND gene. Hum Mol Genet 1996;5:51-59.
7.
Berger W, van de Pol D, Warburg M, Gal A, Bleeker-Wagemakers L, de Silva H, Meindl A, Meitinger T, Cremers F, Ropers HH: Mutations in the candidate gene for Norrie disease. Hum Mol Genet 1992b;1:461-465.
8.
Chow CC, Kiernan DF, Chau FY, Blair MP, Ticho BH, Galasso JM, Shapiro MJ: Laser photocoagulation at birth prevents blindness in Norrie's disease diagnosed using amniocentesis. Ophthalmology 2010;117:2402-2406.
9.
Halpin C, Owen G, Gutierrez-Espeleta GA, Sims K, Rehm HL: Audiologic features of Norrie disease. Ann Otol Rhinol Laryngol 2005;114:533-538.
10.
Kondo H, Qin M, Kusaka S, Tahira T, Hasebe H, Hayashi H, Uchio E, Hayashi K: Novel mutations in Norrie disease gene in Japanese patients with Norrie disease and familial exudative vitreoretinopathy. Invest Ophthalmol Vis Sci 2007;48:1276-1282.
11.
Meindl A, Berger W, Meitinger T, van de Pol D, Achatz H, Dorner C, Haasemann M, Hellebrand H, Gal A, Cremers F, et al: Norrie disease is caused by mutations in an extracellular protein resembling C-terminal globular domain of mucins. Nat Genet 1992;2:139-143.
12.
Meitinger T, Meindl A, Bork P, Rost B, Sander C, Haasemann M, Murken J: Molecular modelling of the Norrie disease protein predicts a cystine knot growth factor tertiary structure. Nat Genet 1993;5:376-380.
13.
Parving A, Warburg M: Audiological findings in Norrie's disease. Audiology 1977;16:124-131.
14.
Perez-Vilar J, Hill RL: Norrie disease protein (norrin) forms disulfide-linked oligomers associated with the extracellular matrix. J Biol Chem 1997;272:33410-33415.
15.
Rehm HL, Zhang DS, Brown MC, Burgess B, Halpin C, Berger W, Morton CC, Corey DP, Chen ZY: Vascular defects and sensorineural deafness in a mouse model of Norrie disease. J Neurosci 2002;22:4286-4292.
16.
Richter M, Gottanka J, May CA, Welge-Lussen U, Berger W, Lutjen-Drecoll E: Retinal vasculature changes in Norrie disease mice. Invest Ophthalmol Vis Sci 1998;39:2450-2457.
17.
Rozen S, Skaletsky H: Primer3 on the www for general users and for biologist programmers. Methods Mol Biol 2000;132:365-386.
18.
Sims KB, de la Chapelle A, Norio R, Sankila EM, Hsu YP, Rinehart WB, Corey TJ, Ozelius L, Powell JF, Bruns G, et al: Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 1989;2:1069-1076.
19.
Smith SE, Mullen TE, Graham D, Sims KB, Rehm HL: Norrie disease: extraocular clinical manifestations in 56 patients. Am J Med Genet A 2012;158A:1909-1917.
20.
Walsh MK, Drenser KA, Capone A Jr, Trese MT: Early vitrectomy effective for Norrie disease. Arch Ophthalmol 2010;128:456-460.
21.
Warburg M: Norrie's disease: a new hereditary bilateral pseudo-tumor of the retina. Acta Ophthalmol 1961;39:757-772.
22.
Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J: Vascular development in the retina and inner ear: control by norrin and frizzled-4, a high-affinity ligand-receptor pair. Cell 2004;116:883-895.
23.
Yamada K, Limprasert P, Ratanasukon M, Tengtrisorn S, Yingchareonpukdee J, Vasiknanonte P, Kitaoka T, Ghadami M, Niikawa N, Kishino T: Two Thai families with Norrie disease (ND): association of two novel missense mutations with severe ND phenotype, seizures, and a manifesting carrier. Am J Med Genet 2001a;100:52-55.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.